Clinical Trial Update: Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating pharmacokinetics, safety, tolerability, and efficacy of a new artemether-lumefantrine dispersible tablet in infants and neonates unde…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmodium Falciparum Malaria

Drugs mentioned

• Coartem (artemether-lumefantrine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Plasmodium Falciparum Malaria | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2024-10-03